focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Time to start some defensive rotation?

Wed, 31st Mar 2021 12:57

* European shares up 0.2%

* Deliveroo flops on market debut

* DAX hovers around 15,000 points

* Eyes on Biden infrastructure plan

March 31 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

TIME TO START SOME DEFENSIVE ROTATION? (1157 GMT)

It’s not easy to make the right choice in the stock markets,
amid cyclicals increasingly stretched valuations versus
defensives and expectations of stronger growth and inflation,
coupled with higher bond yields.

Morgan Stanley analysts see “potential catalysts for a
bigger tactical defensive rotation later in the year,” while
they are wary of “rotating too hard just yet.”

“Our expectation for continued strong growth data, prevents
us from wanting to get too defensive just yet, but we think it
makes sense to start to reduce the size of our underweight
stance,” they say in a research note.

Bottom line, they upgrade pharma stocks to neutral, which
they say trade “at a rare PE discount to the wider market,”
while downgrading to neutral consumer services and transport,
“where valuations look increasingly rich.”

BofA says cyclicals “are already pre-pricing an improvement
in macro momentum.”

But “if PMIs rebound to unusually strong levels by Q3 and
bond yields continue to rise, as we expect, this would imply a
further 15% upside for cyclicals versus defensives by Q3,” it
adds. In the table below BofA's forecast overview.

(Stefano Rebaudo)

*****

EUROPE: IN THE MOOD FOR LOVE (1130 GMT)

This has been a fine quarter for European equities which are
set to exit Q1 with a rise of over 8%.

Worth noting that for the first time since Q3 2019, the
STOXX 600 has outperformed the S&P 500 which is up 'only' 5.4%.

Europe, however, remains unloved, Barclays analysts point
out.

"Despite their good relative performance ytd, European
equities remain ignored by global investors", the bank's
analysts write.

"We believe that improving vaccine rollout later this year
and reopening could be the triggers for the region to see
inflows again", they argue, adding that because Europe is
overweight on popular value stocks, it could benefit from
managers rotating their portfolios.

(Julien Ponthus)

*****

NEW RECORD HIGH FOR AMSTERDAM (1018 GMT)

There's been a lot of chatter about the 15,000 points
snatched by the DAX but other indexes in Europe are also
enjoying the end of Q1.

Amsterdam's AEX has just reached a record high of 703.44
points, its highest level since September 2000!

The STOXX 600 is also very close to testing unchartered
highs, just 2 points below its February 2020 record of 433.90
points.

Here's the AEX since 1995:

(Julien Ponthus)

*****

DELIVEROO UNDERDELIVERS (0832 GMT)

Horrible, disastrous... there's no shortage of adjectives
out there to describe the fiasco of Deliveroo which a few
minutes after its London debut saw its shares hit a 271 pence
low, 30% below their 390 pence IPO price tag.

Here is a round up of comments we got so far.

Russ Mould, Investment Director at AJ Bell: "How could a
company that was valued at $3 billion in November, $5 billion in
January, be magically worth 8-9 billion in March - particularly
when according to its own statements it was potentially
requirement in need of emergency funding last year. I guess the
question now is does this mean that we’re about to enter a more
difficult period for these IPOs that loss-making companies
become with very high valuations, which would be an interesting
shift of tone".

Angelo Meda, portfolio manager at Banor SIM: "The wind has
turned on all growth stocks. I don't know if this is a stock
that will recover anytime soon. We stayed out of the IPO because
of concerns over valuation and regulation. Until there is
clarity on riders' rights it will be difficult to invest in this
sector".

Connor Campbell, analyst at Spreadex: "Deliveroo has been
able to grow to the point of launching on the stock market in
part thanks to the exploitation of its workers. Now, said
exploitation is one of the main reasons behind its sour start to
life as a public company, with multiple leading fund managers
expressing concern over its labour practices. It is maybe a case
of a perfectly zeitgeisty company in one sense – Deliveroo is a
primary pandemic beneficiary – coming of age in the wrong
moment, i.e. in the era of ostensible environmental, social and
corporate governance".

James Athey, investment director at Aberdeen Standard
Investments: "The number of institutions lining up to say no on
ESG grounds always looked like it was going to make it a tricky
debut".

Stephane Ekolo global equity strategist at Tradition: "It
stings. Some UK asset managers had warned about work conditions
and the business model and had flagged regulation risks".

Neil Wilson, analyst at Markets.com:
"Chiefly though it reflects the fact that even pricing the IPO
at the bottom of the range, Deliveroo was demanding too high a
price tag for a loss-making delivery platform in a very
competitive space with a questionable path to profitability. The
books were covered, it was just plain mis-priced".

(Julien Ponthus, Danilo Masoni, Elizabeth Howcroft)

*****

DAX RESISTS ABOVE 15K, DELIVEROO FLOPS (0726 GMT)

European shares are off to a muted start this morning with
the main regional benchmark trading just above parity and no
sector taking the lead in either direction.

Germany's DAX is flat but it's managing to hold above the
15,000 points mark it breached yesterday for the first time.

In London, Deliveroo delivered a disappointing debut,
falling as much as 30% from its IPO prices in the first minutes
of life.

Elsewhere, a couple of downgrades are making videogame maker
CD Projekt the biggest faller on the STOXX, down 11%.

Here's your snapshot.

(Danilo Masoni)

*****

SO LONG Q1, U.S. LEADS GOING INTO Q2 (0702 GMT)

The first quarter draws to a close and what a quarter it's
been: an 82 basis-point surge in U.S. Treasury yields on a
stimulus boost the size of which few would have anticipated, a
25% oil price jump, amateurs taking on seasoned hedge funds and
big banks taking big hits from trouble at hedge funds.

But having added some $2.6 trillion in value over the first
three months, MSCI's global equity index is ending the quarter
in a defensive mood. Asian stocks, outside Japan, are down 0.3%,
the Nikkei shed 0.9% and futures point to a weak open for
European bourses. Wall Street futures are flat.

The outlier is the dollar, riding at fresh one-year peaks
against the yen and at multi-month highs versus other major
currencies.

Its gains come as the United States races ahead of the rest
in terms of vaccinations, economic growth and the sheer size of
government spending. And U.S. President Joe Biden will outline
later on Wednesday how he intends to pay for a $3-$4 trillion
infrastructure plan.

That kind of spending will benefit the rest of the world
too; the IMF will raise global growth forecasts for 2021 and
2022, Managing Director Kristalina Georgieva said on Tuesday.

But the Biden plan, and the likelihood of more debt
issuance, also explains this week's bond selloff that's taken
10-year Treasury yields towards 14-months highs at around 1.78%.

In UK markets, trading starts in food delivery company
Deliveroo, whose shares will list at 390 pence each, valuing the
company at 7.6 billion pounds ($10.5 billion). It's the biggest
London IPO for a decade, yet its valuations lag continental
peers Just Eat and Delivery Hero.

Key developments that should provide more direction to
markets on Wednesday:

- Euro zone flash inflation data due; data on Tuesday showed
German inflation topped ECB target in March.

- China's manufacturing expands at the quickest pace in
three months in March.

- Britain's economy grows a stronger-than-expected 1.3% in
Q4.

- Hitachi to buy U.S. software firm GlobalLogic Inc for $9.6
billion.

- Germany to limit the use of AstraZeneca COVID-19
vaccine to people aged 60 and above

- OPEC+ oil producing group is concerned that uncertainties
may impact the recovery in oil demand

- Gold set for worst quarter since 2016.

- U.S. ADP national unemployment, Chicago PMI data due.

- Sweden's H&M swings to Q1 loss

(Dhara Ranasinghe)

*****

DELIVEROO FOR BREAKFAST (0625 GMT)

Today is Deliveroo day!

The food delivery company is making its debut on the London
stock market this morning in what is set to be the biggest IPO
since Glencore back in 2011.

Now, with the Nasdaq easing 0.1% yesterday and tech/growth
shares under pressure, the context is perhaps not ideal.

The S&P technology sector ended down 1% and was
the biggest drag on the S&P 500.

The Nasdaq is on track for its first monthly loss since
November with 10-year U.S. Treasury yields rising
to 1.77%, their highest since Jan. 22.

European futures are also in the red, losing about 0.3% at
the time of writing.

(Julien Ponthus)

*****

More News
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.